| 4.59 Data as of May 24 |  +0.08 / +1.77%Today’s Change | 2.55 Today|||52-Week Range 6.65 | -7.27% Year-to-Date |
| Teva - Alexza Sign Deal for Adasuve - Analyst Blog May 13 / Zacks.com |
| Previous close | 4.51 |
| Today’s open | 4.51 |
| Day’s range | 4.51 - 4.65 |
| Volume | 274,874 |
| Average volume (3 months) | 396,661 |
| Market cap | $79.1M |
| Dividend yield | -- |
| Earnings growth (last year) | +62.67% |
| Earnings growth (this year) | -22.77% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -28.09% |
| P/E ratio | NM |
| Price/Sales | 15.17 |
| Price/Book | 28.13 |
| Today’s change | Today’s % change | |
|---|---|---|
| APRIApricus Biosciences ... | -0.07 | -2.64% |
| MDGNMedgenics Inc | -0.06 | -1.44% |
| ZLCSZalicus Inc | -0.00 | -0.25% |
| CBLICleveland BioLabs In... | +0.02 | +1.22% |
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.51 |
| Annual revenue (last year) | $4.1M |
| Annual profit (last year) | -$28.0M |
| Net profit margin | -687.42% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Thomas Braxton King, MBA |
Senior Vice President-Operations & Manufacturing Michael J. Simms, MBA |
Corporate headquarters Mountain View, California |
.
